Chief Executive Officer

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

Methods for treating peripheral t-cell lymphoma

Indolent Lymphoma Market Expected to Grow at a CAGR of 6.11% during 2025-2035, Impelled by Advancements in Novel Targeted Therapies

Secura Bio Appoints Dr. Patrick Vink as Chairman of the Board of Directors

Key Account Manager

Secura Bio, Inc. is dedicated to bridging the gap between innovative oncology therapies and the patients who need them. They are seeking a Key Account Manager responsible for promoting Copiktra to targeted healthcare providers while ensuring compliance with company policies and improving customer awareness and sales within their territory.

Sign up with Google

Sign in with Google